Table 1 Biologic treatments details: type of treatments (Eligible patients)
Reference biologic treatment line | Eligible patients N = 669 n (%) |
|---|---|
Secukinumab (Cosentyx) | 274 (41.0%) |
Ustekinumab (Stelara) | 169 (25.3%) |
Adalimumab (Humira) | 87 (13.0%) |
Ixekizumab (Taltz) | 81 (12.1%) |
Certolizumab | 19 (2.8%) |
Etanercept (Enbrel) | 17 (2.5%) |
Etanercept (Benepali) | 13 (1.9%) |
Adalimumab (Amgevita) | 5 (0.7%) |
Golimumab | 3 (0.4%) |
Adalimumab (Imraldi) | 1 (0.1%) |